Sahil Kirpekar, MD

Chief Business Officer atai Life Sciences

As the Chief Business Officer at atai Life Sciences, Dr. Kirpekar is responsible for portfolio strategy and capital allocation, internal and external investments, as well as early commercial capabilities for atai’s pipeline in neuro-psychiatry. Dr. Kirpekar’s tenure at Otsuka Pharmaceutical Co., Ltd., where he last served as the Head of Business Development and Co-chair of the Global Business Development Committee, demonstrated his ability to build a successful pipeline of assets in CNS, rare disease, and Haem-Oncology. He has been the architect of several complex deals, and his leadership and strategic acumen led to the closing of significant transactions valued at more than $2.7 billion, contributing to the on-going growth and success of the company.

Dr. Kirpekar’s diverse experience extends beyond his time at Otsuka. As a strategy consultant at Double Helix Consulting (McCann Health Consulting), he developed and executed commercial and market access strategies for biopharmaceutical companies worldwide. Dr. Kirpekar’s multifaceted background as a trained physician makes him a compassionate and empathetic leader while giving him the necessary scientific depth as he tackles key strategic questions. He sees the bigger picture, and ultimately is driven by his commitment to patients in need.

Our website uses cookies, including third parties’ profiling cookies, to improve the functionality of the site and your user experience. You can learn more about how we use cookies and how to change your cookies settings in our Privacy Policy. By closing this message, clicking below or continuing to use this site, you consent to our use of cookies.